Last reviewed · How we verify

NCT06176105: MATER

Mortality After Transfusion of Ever-pregnant Donor Red Blood Cells

Completed Last updated 19 December 2023
What this trial tests

trial in Anemia in 101,000 participants. Completed in 1 October 2020.

Timeline
1 October 2019
Primary endpoint
1 October 2020
1 October 2020

Quick facts

Lead sponsorSanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
StatusCompleted
Study typeOBSERVATIONAL
Enrollment101,000
Start date1 October 2019
Primary completion1 October 2020
Estimated completion1 October 2020
Sites1 location across Netherlands

Conditions studied

Sponsor

Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research

Who can join

Eligibility, any sex, with Anemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The MATER study is an observational cohort study on first ever transfusion recipients in six hospitals in the Netherlands, with information collected on both donor and patient characteristics. We aim to further specify which combination of characteristics of both donors and patients determine the increased risk of mortality after blood transfusions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anemia

Currently open trials in the same condition.

Other Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06176105.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing